Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Przewlekłe leczenie przeciwkrzepliwe

Przewlekłe leczenie przeciwkrzepliwe AbstractUnprovoked venous thromboembolism (VTE) - proximal venous thrombosis or pulmonary embolism - should be treated either 3 months or indefinitely if the risk of bleeding is low. This article summarizes the efficacy and safety of extended therapy of VTE with direct oral anticoagulants (DOAC) in comparison with warfarin, as well as the role of of acetylsalicylic acid (ASA) for the long-term prevention of recurrent VTE. As the Survet study showed, for some patients who have already completed at least 6 months of anticoagulant treatment for their index VTE event, an oral glycosaminoglycan - sulodexide associated with compression therapy is a good choice, because it decreases the incidence of recurrences of VTE without detectable risks for the patients’ safety. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Haematologica Polonica de Gruyter

Przewlekłe leczenie przeciwkrzepliwe

Zawilska, Krystyna
Acta Haematologica Polonica , Volume 49 (2): 3 – Aug 30, 2018
Download PDF
3 pages

Loading next page...
 
/lp/de-gruyter/przewlek-e-leczenie-przeciwkrzepliwe-0ThR10g0pI

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
de Gruyter
Copyright
© 2018 Polish Society of Hematology and Transfusion Medicine, Insitute of Hematology and Transfusion Medicine, Published by Sciendo
eISSN
2300-7117
DOI
10.2478/ahp-2018-0009
Publisher site
See Article on Publisher Site

Abstract

AbstractUnprovoked venous thromboembolism (VTE) - proximal venous thrombosis or pulmonary embolism - should be treated either 3 months or indefinitely if the risk of bleeding is low. This article summarizes the efficacy and safety of extended therapy of VTE with direct oral anticoagulants (DOAC) in comparison with warfarin, as well as the role of of acetylsalicylic acid (ASA) for the long-term prevention of recurrent VTE. As the Survet study showed, for some patients who have already completed at least 6 months of anticoagulant treatment for their index VTE event, an oral glycosaminoglycan - sulodexide associated with compression therapy is a good choice, because it decreases the incidence of recurrences of VTE without detectable risks for the patients’ safety.

Journal

Acta Haematologica Polonica – de Gruyter

Published: Aug 30, 2018

References

  • The efficacy of sulodexide in the prevention of postthrombotic syndrome
    Luzzi
  • AMPLIFY - EXT Investigators Apiban for extended treatment of venous thromboembolism
    Agnelli
  • Gal Systematic review : case - fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism Antithrombotic therapy for VTE disease : CHEST guideline and expert panel report
    Carrier
  • Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism : a meta - analysis
    Linkins
  • ASPIRE Investigators Low - dose aspirin for preventing recurrent venous thromboembolism
    Brighton
  • SURVET Study Investigators Sulodexide for the prevention of recurrent venous thromboembolism : the sulodexide in secondary prevention of recurrent deep vein thrombosis study : a multicenter , randomized double - blind , placebo - controlled trial
    Andreozzi
  • RE - MEDY Trial Investigators RE - SONATE Trial Investigators Extended use of dabigatran , warfarin or placebo in venous thromboembolism
    Schulman
  • Death and disability from warfarin - associated intracranial and extracranial hemorrhages
    Fang
  • for the EINSTEIN CHOICE Investigators Rivaroxaban or aspirin for extended treatment of venous thromboembolism
    Weitz
  • Guidance for the treatment of deep vein thrombosis and pulmonary embolism
    Streiff
  • The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism A prospective cohort study in patients
    Pradoni
  • Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism
    Kearon
  • WARFASA Investigators Aspirin for preventing the recurrence of venous thromboembolism
    Becattini